Innovators in Thrombosis
The Thrombosis Research Institute is dedicated to bringing new solutions to patients for the detection, prevention and treatment of blood clots. Our programme of research was first established in the 1960s and since then our work has changed the lives of those at risk of thrombosis through the use heparin for its prevention, and the pioneering use of the low molecular weight heparins. Today we remain one of the few academic research institutes solely devoted to working in thrombosis.
At TRI, our research is driven by the needs of patients so that innovations and new treatments flow seamlessly from theory to practice. TRI has become a world leader in the developing field of real-world outcomes research, developing and executing pioneering global programmes.
Our success comes through partnership with a network of more than 2,500 research centres in around 40 countries. Bringing the quality of our data and the rigour of clinical trials to real-world studies, our operation models have extended quality research to under-represented countries, care settings and patients. Through our registries, we seek to strengthen the chain of evidence beyond clinical trials and hope to create new data to improve healthcare delivery and patient outcomes.
The Thrombosis Research Institute is investigating emerging health technologies, including Artificial Intelligence and Machine Learning, which are providing data-driven insights on clinical care. We envision a future using intelligent modelling and “big data” from apps and the web to develop cutting edge models for connected care.
The pioneering programme of research now recognisable as TRI was established. It delivered breakthrough solutions in thrombosis which have saved millions of lives and this innovation continues today, across medical disciplines and around the world.
TRI was established as an independant institute, with the backing of the then Prime Minister, Margaret Thatcher, specifically to conduct research into thrombosis, a major cause of death and disability throughout the world.
2000 - now
TRI is now acknowledged as a leader in clinical research and real-world evidence, bringing the quality of data and rigour of clinical trials to real-world studies, and shaping the design of new registries.
Professor Vijay Kakkar OBE
Vijay Kakkar was Founder of the Thrombosis Research Institute, London and Founder, Scientific Chairman and Managing Trustee of the Thrombosis Research Institute, Bangalore and Emeritus Professor of the University of London.
He was the recipient of a number of distinctions and awards including:
A Hunterian Professorship from the Royal College of Surgeons, the Gunnar Bayer Memorial Lecture, the David Patey prize of the Surgical Society of Great Britain and Ireland, Visting Professor of Harvard University, the James Finalyson Memorial Lecture, the Cross Memorial Lecture, the Wright-Schultz award from the International Society of Thrombosis and Haemeostasis for original and outstanding contribution in Thrombosis Research, the Freyer Memorial Lecture, Hon Fellowships of the Academy of Medicine in Singapore and the Association of Surgeons of India, a Lifetime achievement award from the International Union of Angiologoy for outstanding leadership in the investigation of thrombotic disorders and an annual award for medicine from the Guild of British Asians for outstanding contribution by Asian doctors to British medicine.
He was Founder President of the British Society of Haemostasis and Thrombosis and Founder President of the South Asian Society of Atherosclerosis and Thrombosis.
On his retirement from the University in 1997, he was awarded the title of Emeritus Professor of the University of London. His publications include over 680 original articles, six books and contributions to 44 text books.